Nakamichi, Shinji
Kubota, Kaoru http://orcid.org/0000-0003-0367-2606
Zou, Fenfei
Hayashi, Anna
Takano, Natsuki
Onda, Naomi
Matsumoto, Masaru
Miyanaga, Akihiko
Noro, Rintaro
Seike, Masahiro
Article History
Received: 3 January 2023
Accepted: 16 April 2023
First Online: 12 May 2023
Declarations
:
: Dr. Kubota received research fund from Nihon Kayaku, AstraZeneca and payment or honoraria for lectures and presentations from Chugai Pharmaceutical. Dr. Seike received payment or honoraria for lectures and presentations from AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical, MSD, Ono Pharmaceutical, Bristol–Myers Squibb, Eli Lilly Japan, Takeda Pharmaceutical, Nihon Kayaku, Nippon Boehringer Ingelheim, Pfizer, Kyowa–Hakko Kirin, and Novartis. No other disclosures were reported.
: The protocol of this study was approved by the Institutional Review Board of Nippon Medical School Hospital (B-2022-538).